ElectroCore - Articles and news items

ElectroCore’s non-invasive vagus nerve (nVNS) stimulation therapy shown to be safe and to produce no meaningful cardiac adverse effects

Industry news / 28 April 2015 / Victoria White

Open-label trial shows electroCore’s nVNS therapy does not cause any meaningful cardiovascular adverse effects in patients with asthma…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+